Patents by Inventor Johannes Henricus Nuijens

Johannes Henricus Nuijens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
    Patent number: 9211318
    Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: December 15, 2015
    Assignee: PHARMING INTELLECTUAL PROPERTY B.V.
    Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
  • Use Of C1 Inhibitor For The Prevention Of Ischemia-Reperfusion Injury
    Publication number: 20130244941
    Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.
    Type: Application
    Filed: February 25, 2013
    Publication date: September 19, 2013
    Applicant: PHARMING INTELLECTUAL PROPERTY B.V.
    Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
  • Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
    Patent number: 8415288
    Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: April 9, 2013
    Assignee: Pharming Intellectual Property B.V.
    Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
  • USE OF C1 INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
    Publication number: 20120088728
    Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.
    Type: Application
    Filed: October 11, 2011
    Publication date: April 12, 2012
    Applicant: PHARMING INTELLECTUAL PROPERTY B.V.
    Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
  • Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
    Patent number: 8071532
    Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: December 6, 2011
    Assignee: Pharming Intellectual Property B.V.
    Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
  • C1 inhibitor with short half-life transient treatment
    Patent number: 7544853
    Abstract: The present invention relates to the use of a C1 inhibitor (C1INH) with shorter half-life than plasma-derived C1INH for the preparation of a medicament for the transient treatment of an individual. It relates to both therapeutic and prophylactic treatment. The method of the invention allows for the administration of C1INH at certain therapeutic levels for a concise pre-determined time span. Pharmaceutical compositions based on C1INH with shorter half-lives may be used both in situations where transient treatment is merely and advantage. The advantage of the use according to the invention is that an individual is not exposed to C1INH for longer than required, since the levels of the C1INH more rapidly subsides after administration has stopped. In contrast, levels of plasma-derived C1INH would remain elevated for a prolonged period of time.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: June 9, 2009
    Assignee: Pharming Intellectual Property B.V.
    Inventor: Johannes Henricus Nuijens
  • Use of C1 Inhibitor for the Prevention of Ischemia-Reperfusion Injury
    Publication number: 20080305993
    Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.
    Type: Application
    Filed: December 19, 2006
    Publication date: December 11, 2008
    Applicant: Pharming Intellectual Property B.V.
    Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
  • C1 Inhibitor produced in the milk of transgenic mammals
    Publication number: 20030140358
    Abstract: The invention provides transgenic nonhuman mammals expressing C1 inhibitor in their milk. The C1 inhibitor is useful in treating patients with hereditary angioedema or patients requiring immunosuppression.
    Type: Application
    Filed: July 17, 2002
    Publication date: July 24, 2003
    Inventors: Johannes Henricus Nuijens, Henricus Antonius Van Veen, Frank Robert Pieper, Jonis Jan Heus
  • C1 inhibitor with short half-life transient treatment
    Patent number: RE43691
    Abstract: The present invention relates to the use of a C1 inhibitor (C1INH) with shorter half-life than plasma-derived C1INH for the preparation of a medicament for the transient treatment of an individual. It relates to both therapeutic and prophylactic treatment. The method of the invention allows for the administration of C1INH at certain therapeutic levels for a concise pre-determined time span. Pharmaceutical compositions based on C1INH with shorter half-lives may be used both in situations where transient treatment is merely and advantage. The advantage of the use according to the invention is that an individual is not exposed to C1INH for longer than required, since the levels of the C1INH more rapidly subsides after administration has stopped. In contrast, levels of plasma-derived C1INH would remain elevated for a prolonged period of time.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: September 25, 2012
    Assignee: Pharming Intellectual Property B.V.
    Inventor: Johannes Henricus Nuijens